BRIEF REPORT |
Correspondence to: Enrico Crivellato, Dept. of Medical and Morphological Researches, Anatomy Section, P.le Kolbe, n.3, 33100 Udine, Italy. E-mail: enrico.crivellato@drmm.uniud.it
![]() |
Summary |
---|
![]() ![]() ![]() ![]() |
---|
Several fluorescent probes have been used in functional studies to analyze drug transport in multidrug-resistant cells by fluorescent microscopy. Because many of these molecules have some drawbacks, such as toxicity, nonspecific background, or accumulation in mitochondria, new fluorescent compounds have been proposed as more useful tools. Among these substances, Bodipy-FLVerapamil, a fluorescent conjugate of the drug efflux blocker verapamil, has been used to study P-glycoprotein activity in different cell types. In this study we tested by fluorescent microscopy the accumulation of Bodipy-FLVerapamil in cell lines that overexpress either P-glycoprotein (P-gp) or multidrug resistance-related protein 1 (MRP1). Expression of P-gp and MRP1 was evaluated at the mRNA level by RT-PCR technique and at the protein level by flow cytometric analysis using C219 and MRP-m6 monoclonal antibodies. Results indicate that Bodipy-FLVerapamil is actually a substrate for both proteins. As a consequence, any conclusion about P-gp activity obtained by the use of Bodipy-FLVerapamil as fluorescent tracer should be interpreted with caution. (J Histochem Cytochem 50:731734, 2002)
Key Words: Bodipy-FLVerapamil, P-glycoprotein, multidrug resistance-related, Protein 1, fluorescence microscopy
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() |
---|
MULTIDRUG RESISTANCE (MDR) is one of the most important mechanisms of chemioresistance and a major problem in cancer chemotherapy. Primary or secondary chemioresistance is often mediated by overexpression of P-glycoprotein (P-gp) and/or multidrug resistance-related protein (MRP), both of which belong to the ATP-binding cassette (ABC) superfamily of membrane transport proteins (
The availability of fluorescent molecules that are substrates for either P-gp or MRP is, of course, of great relevance in the attempt to predict the efficacy of chemotherapeutic strategies in clinical and experimental oncology. A series of fluorescent compounds, such as anthracyclines, acridines, calcein-AM, and rodamine 123, has been classically used to test P-gp activity (
In this study we tested by fluorescent microscopy the accumulation of BFLV in cell lines that overexpress either P-gp or MRP1. Single-cell microscopic analysis was carried out in the presence or absence of specific P-gp or MRP1 inhibitors. Expression of P-gp and MRP was evaluated at the mRNA level by the reverse transcriptase-polymerase chain reaction (RT-PCR) technique and at the protein level by flow cytometric analysis (FCA) using specific anti-P-gp and anti-MRP1 monoclonal antibodies.
Three cell lines were used in our study. The doxorubicin-resistant counterpart of the murine lymphoid neoplasm P388 (P388/ADR) was obtained from the NCI Frederick Cancer Research Facility/DC Tumor Repositor (Bethesda, MD) and was grown in suspension in RPMI 1640 medium supplemented with 10% fetal calf serum. The doxorubicin-resistant counterpart (LLC-PK1/ADR) of the pig kidney epithelial cell line LLC-PK1 (American Type Culture Collection, Rockville, MD; ATCC CRL-1392), was obtained in our laboratory by selection with doxorubicin as described previously (
The expression of P-gp and MRP1 at the mRNA level was evaluated by RT-PCR. Total RNA was extracted by SV total RNA Isolation Kit (Promega; Milano, Italy). Five µg of total RNA were reverse transcribed using Superscript II RNAse H (Gibco BRL Life Technologies; San Giuliano Milanese, Italy) and the cDNA (0.51 µl) was used in the PCR reaction in a final volume of 10 µl. Synthetic oligonucleotide primers (Invitrogen Life Technologies; San Giuliano Milanese) were used to investigate the presence of MDR1, mdr1a, mdr1b, and MRP1 mRNA transcripts. The primer sequences are listed in the legend to Fig 1. The amplification by Taq polymerase was performed using a DNA thermal cycler PTC 100 MJ Research. After denaturing at 94C for 5 min, the reaction was conducted for 2035 cycles at different annealing temperatures, as indicated in the legend to Fig 1. For all primers, the reaction ended with a final step at 72C for 10 min. PCR products were subjected to electrophoresis on a 1.5% agarose gel and were visualized by ethidium bromide staining. To normalize the PCR data, primers amplifying a fragment of ß-actin were used. The DNA marker was from SigmaAldrich (100-bp ladder).
|
The expression of P-gp and MRP1 at the protein level was studied by FCA using the murine C219 (CIS Bio International; Gif-sur-Yvette, France) and MRP-m6 (Chemicon International; Temecula, CA) monoclonal antibodies (MAbs), which are specific for detection of P-gp and MRP1, respectively. A total of 5 x 106/ml cells were fixed in 0.2% (v/v) paraformaldehyde solution in 100% acetone for 30 sec (for detection of C219 immunoreactivity) or with 100% ethanol at -20C for 15 min (for detection of MRP-m6 immunoreactivity). After the fixation step, the cells were centrifuged at 400 x g for 10 min at 4C, washed with 0.01 M PBS containing 3% bovine serum albumin (BSA), and resuspended in the same buffer. The primary antibodies C219 (510 µg/ml) and MRPm6 (1.252.5 µg/ml) were added to aliquots of 200 µl cells (about 1 x 106 cells). To determine the nonspecific staining, the respective isotypic controls IgG2a (510 µg/ml) and IgG1 (1.252.5 µg/ml) were also used (SigmaAldrich). After 1-hr incubation at room temperature (RT), the cells were washed twice with PBS3% BSA and finally re-suspended in PBS3% BSA containing the fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgG secondary antibody (SigmaAldrich; 1:100). Incubation continued for 30 min at RT in the dark. Cells were then washed in PBS, resuspended in a final volume of 500 µl PBS, and subjected to FCA. FCA was performed by an EPICS ELITE EPS Coulter equipped with an argon/ion laser excitation source emitting at 488 nm. FITC fluorescence was collected through a 525-nm bandpass filter. At least 20,000 cells were analyzed and gated on the basis of the forward and sideward scatter. The green fluorescence amount was measured using log mode amplification. For the measure of intensity of the staining, the fluorescence index (FI) was calculated, which represents the ratio between the mean fluorescence intensity of cells stained with the specific antibody and that of cells stained with the isotypic control antibody in immunofluorescence experiments.
Intracellular accumulation of BFLV (Molecular Probes; Eugene, OR) was studied by fluorescence microscopy. For single-cell microscopic analysis, LLC-PK1/ADR and PANC-1 cells were seeded in Leighton tubes at a cell density of 2 x 104 cells/ml in 1 ml of complete culture medium, and the uptake of BFLV was observed on confluent cells on the fifth day after inoculation. P388/ADR cells at a cell density of 1 x 106 cells/ml were also used. Cells were incubated for specified periods in the absence or presence of substances known to modulate P-gp, such as verapamil and vinblastine (both from SigmaAldrich), or MRP activity, such MK571 (Biomol Research Lab; Plymouth Meeting, PA). Cells were examined under a Zeiss Axioskop microscope equipped with a mercury lamp (Osram HBO, 100 W; Oberkochen, Germany) for epifluorescence examination. BFLV was observed under appropriate excitation/emission filter setting conditions (excitation at 480 nm, emission at 510 nm) with fluorescein optics.
As expected, P388/ADR cells, which overexpressed P-gp at both the mRNA and the protein level but did not express MRP1 products (Fig 1, Fig 2A, and Fig 2B), exhibited a marked increase of intracellular BFLV-related fluorescence when treated with P-gp inhibitors, such as verapamil or vinblastine, but were unresponsive to MK571 (Fig 3A3C). Incubation of P-gp-overexpressing LLC-PK1/ADR cells with inhibitors of P-gp activity induced a bright punctate cytoplasmic fluorescence (Fig 3D and Fig 3E). Under the same experimental conditions, PANC-1 cells exhibited a weak fluorescence intensity (Fig 3H), according to the lower mRNA and protein expression of P-gp found in this cell line (Fig 1 and Fig 2B). Inhibition of MRP1 activity in LLC-PK1/ADR and in PANC-1 cells by the specific MRP blocker MK571 led to accumulation of BFLV in both cell lines (Fig 3F and Fig 3I). However, the intensity of intracellular fluorescence was higher in PANC-1 cells than in LLC-PK1/ADR cells, in line with the overexpression of MRP1 found in the former cell type by both RT-PCR (Fig 1) and FCA (Fig 2B).
|
|
In conclusion, this study demonstrates that the fluorescent compound BFLV should not be considered a specific substrate for P-gp. Experimental data indeed provide evidence that this molecule is also transported by MRP1. BFLV is undoubtedly a useful tool for screening and analytical studies of the MDR phenotype in many tumor cell types. In fact, it is nontoxic at the currently used concentrations and exhibits a strong and stable intrinsic fluorescence without fluorescent background. However, because BFLV is also a substrate for P-gp and MRP1, any result on P-gp activity obtained with this compound should be interpreted with caution.
![]() |
Acknowledgments |
---|
Supported by grants from Lega Italiana per la Lotta contro i Tumori, Sezione Friulana "Elio ed Enrico Morpurgo," the Ministero Università e Ricerca Scientifica e Tecnologica 60%, and Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale.
Received for publication January 22, 2002; accepted January 23, 2002.
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() |
---|
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398[Medline]
Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302
Candussio L, Crivellato E, Rosati AM, BartoliKlugmann F, Granzotto M, Giraldi T, Decorti G (2001) Expression and function of P-glycoprotein and absence of multidrug resistance-related protein in rat and beige mouse peritoneal mast cells. Histochem J 33:259-266[Medline]
Crivellato E, Candussio L, Rosati AM, Decorti G, Klugmann FB, Mallardi F (1999) Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport. Histochem J 31:635-643[Medline]
Decorti G, Rosati A, Candussio L, Giraldi T, BartoliKlugmann F (2001) Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK 1(cell line and its resistant counterpart. Biochem Pharmacol 61):61-66
Kessel D, Beck WT, Kukuruga D, Schulz V (1991) Characterization of multidrug resistance by fluorescent dyes. Cancer Res 51:4665-4670[Abstract]
Kühnel JM, Perrot JY, Marie JP, Schwaller MA (1997) Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia 11:1147-1155[Medline]
Lelong HI, Guzikowski AP, Haugland RP, Pastan I, Gottesman MM, Willingham MC (1991) Fluorescent verapamil derivative for monitoring activity of the multidrug transporter. Mol Pharmacol 40:490-494[Abstract]
Simmons NL, Hunter J, Jepson A (1995) Targeted delivery of a substrate for P-glycoprotein to renal cysts in vitro. Biochim Biophys Acta 1237:31-36[Medline]
Tosi PF, Radu D, Nicolau C (1995) Immune response against the murine MDR1 protein induced by vaccination with synthetic lipopeptides in liposomes. Biochem Biophys Res Commun 212:494-500[Medline]